Identifying Recurrence After Treatment for Cervical Intraepithelial Neoplasia

Optimal follow-up procedures and schedules remain uncertain, but HPV testing looks increasingly useful.

The risk for recurrent dysplasia after treatment for cervical intraepithelial neoplasia (CIN) is unclear, and guidelines for duration of more-intensive follow-up vary from a few years (Netherlands) to 20 years (U.S.). Investigators used nationwide Dutch data from 1994 through 2006 to assess whether women who completed CIN therapy remained at elevated risk for cervical cancer. Following 2 years of posttreatment follow-up with negative cytologic results, cervical cancer was diagnosed at a rate 4.2 times greater than among women with no histories of CIN, suggesting that these women remain at elevated risk for recurrent CIN and cervical cancer.

In another study, British investigators modeled the cost-effectiveness of HPV plus cytologic testing a…

Reviewing Author

Anna Wald, MD, MPH

Disclosures

Consultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)

RoyaltiesUpToDate

Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris

Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases

Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)